MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline

The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.